Business Wire

BDA

6.4.2021 21:47:05 CEST | Business Wire | Press release

Share
BDA to Spotlight Bermuda Market at RIMS Virtual Conference

The Bermuda Business Development Agency (BDA) will host a virtual panel discussion on Bermuda’s liability market and a Bermuda networking break as part of RIMS, the risk management society® annual conference, a comprehensive risk management event that connects and informs the risk management community. The BDA is proud to be a diamond sponsor of this year’s event, RIMS LIVE, which takes place from April 19–30.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210406006077/en/

The panel, titled “Changes and Trends in Liability Risk,” will be held on April 22 from 2–3 p.m. ADT. The session will feature Judy Gonsalves, division president at Chubb Bermuda; Saadia Savory, vice president and head of casualty Bermuda at Aspen Insurance; and Kirsten Beasley, interim head, Willis Towers Watson Bermuda. Moderated by Jasmine DeSilva, the BDA’s business development manager for risk and insurance solutions, the panel will explore the current state of the liability market, emerging trends, and the Bermuda market’s response.

“RIMS is the largest risk event of the year — it is a staple in the calendar and the Bermuda market has proudly attended for more than 35 years,” BDA’s CEO Roland Andy Burrows said. “The BDA and Bermuda are extensively committed to supporting and growing the risk management industry here, and participating in the RIMS annual conference is a key part of that. Bermuda continues to work hard to remain at the forefront of commercial trends and drives innovation forward as one of the world’s most important insurance and reinsurance hubs.”

For those who want to connect with Bermuda and the BDA, or find out more, the BDA will host a virtual booth where delegates can learn more about the market, view videos, and engage in live chat. Delegates can also schedule video meetings.

On a lighter note, the BDA will be bringing Bermuda to the attendees during the “Take a Break in Bermuda” networking event on April 20 at 4:30 p.m. ADT, providing an opportunity to hear from the Premier of Bermuda, the Hon. E. David Burt, JP, MP; Bermuda’s Minister of Finance, the Hon. Curtis Dickinson, JP, MP; and BDA CEO Roland Andy Burrows, who will all be speaking from the beautiful Hamilton Princess & Beach Club.

Also from the Hamilton Princess, Jasmine DeSilva and Andrew Holmes, Bermuda brand director for Goslings, will make Bermuda’s famous Rum Swizzle cocktail in Sheila Gosling’s Maytag vintage washing machine from 1964 — the same appliance Bermuda’s late social queen used to prepare drinks in the 1960s. The BDA will also announce the winner of an all-expenses paid trip to Bermuda, including a stay at the Hamilton Princess.

For more information on RIMS and to register for the conference, click here . To schedule a meeting with a BDA team member, please email jasmine@bda.bm or olivia@bda.bm . For more information on the BDA, click here .

CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye